Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinoma.

Abstract

4109 Background: Docetaxel (DOC) and gemcitabine (GEM) are active against pancreatic cancer. GEM is a potent radiosensitizer. Rigas et al have reported an every-two week schedule of DOC and GEM. We have defined the maximum tolerated dose of GEM twice weekly when given with radiotherapy (XRT) in pancreatic cancer. We are conducting a Phase II trial to… (More)

Topics

Cite this paper

@article{Pipas2004DocetaxelgemcitabineFB, title={Docetaxel/gemcitabine followed by gemcitabine and radiotherapy in patients with pancreatic adenocarcinoma.}, author={J. Marc Pipas and Richard J. Barth and Bassem I Zaki and Thomas Anthony Colacchio and Stuart R. Gordon and John E. Sutton and Gregory H. Ripple and Michael J. Tsapakos and Justin M M Cates and Raymond P Perez}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2004}, volume={22 14_suppl}, pages={4109} }